EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Effectiveness of incretin receptor agonists compared to metreleptin in partial lipodystrophy: a retrospective study

Brandon M Podyma, Marissa Lightbourne, Rebecca J Brown

Journal of the Endocrine Society · 2026-11-02 · 10 (12)

DOI: 10.1210/jendso/bvag248 ↗
AbstractBibliografische Angaben

Abstract

Abstract Context Lipodystrophy syndromes are rare disorders of abnormal fat distribution and metabolic disease. The only approved therapy for generalized lipodystrophy is recombinant leptin (metreleptin), which is not approved for partial lipodystrophy. Recent data suggest efficacy of glucagon-like peptide-1 receptor agonists and glucagon-like peptide-1 receptor agonist/glucose-dependent insulinotropic polypeptide (GIP) dual agonists (collectively referred to as incretins) to treat complications of lipodystrophy. Objective To compare metabolic outcomes of incretin therapies vs metreleptin in partial lipodystrophy. Design Retrospective review of patients who received metreleptin as part of a clinical trial and incretins during routine care under a natural history study. Setting NIH Clinical Center. Patients Twelve female patients with partial lipodystrophy, aged 16-85 years. All but 1 patient had diabetes. Intervention Eleven patients with partial lipodystrophy were treated with metreleptin (mean duration 104 ± 38 months) before switching to incretin therapy (duration 32 ± 13 months). A twelfth patient took metreleptin and an incretin concurrently. Main outcome measures Outcome measures included hemoglobin A1c, insulin dose, Matsuda index, insulinogenic index, disposition index, fasting glucose and insulin, homeostatic model of beta cell function (HOMA-B), homeostatic model assessment of insulin resistance (HOMA-IR), weight, lipids, liver elastography, and liver steatosis. Results Hemoglobin A1c was significantly lower during incretin vs metreleptin treatment (mean difference −1.1 ± 0.4%, range −4.75% to −0.1%, P = .005), associated with modest weight reduction (mean difference −1.5 ± 3.9 kg, range −10.4 to 3 kg, P = .046). Most other metabolic parameters did not differ significantly between treatment periods. Conclusion In patients with partial lipodystrophy, incretins may provide better diabetes control than metreleptin, with comparable control of other metabolic parameters.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →